While Pfizer India has applied to drug regulator for permission to import its experimental mRNA vaccine for sale and distribution without the requirement for local clinical trials, Serum Institute of India, AstraZeneca's India vaccine partner, has applied for emergency use authorisation using data from Phase-III trials that were conducted locally, as well as in Brazil and the UK.
Hyderabad-based Bharat Biotech has sought nod Covaxin which is being indigenously developed in collaboration with the Indian Council of Medical Research (ICMR).
The applications mean that a mass vaccine effort could be shortly underway in a nation that has the world's second-largest coronavirus caseload.
At the IMC, PM Modi said, "We need to work together to ensure a timely roll-out of 5G to leapfrog into the future and empower millions of Indians."
The Prime Minister also pitched for making India a global hub for telecom equipment, design, development, and manufacturing.
Speaking on mobile technology, he said it was because of this that the government was able to provide benefits worth billions of dollars to millions of Indians.
"It is because of mobile technology that we are seeing billions of cashless transactions which boost formalisation and transparency. It is because of mobile technology that we will enable smooth contactless interface on toll booths," PM Modi said.